Search
CAMP4 Therapeutics Corp
CAMPAdd to Watchlist
3.840USD
+0.120+3.23%
Close 09-23 16:00（ET）
199.41MMarket Cap
LossP/E TTM
About CAMP4 Therapeutics Corp Company
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
CAMP4 Therapeutics Corp Profile
Ticker SymbolCAMP
Company nameCAMP4 Therapeutics Corp
IPO dateOct 11, 2024
CEOMandel-Brehm (Josh)
Number of employees55
Security typeOrdinary Share
Fiscal year-endOct 11
AddressOne Kendall Square
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16176518867
Websitehttps://www.camp4tx.com/
Ticker SymbolCAMP
IPO dateOct 11, 2024
CEOMandel-Brehm (Josh)
Company Executives of CAMP4 Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
284.97K
+2.30%
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
284.97K
+2.30%
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
284.97K
+2.30%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
186.39K
+8.79%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
186.39K
+8.79%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
186.39K
+8.79%
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Ms. Kelly Gold
Ms. Kelly Gold
Chief Financial Officer
Chief Financial Officer
74.43K
+8.80%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
284.97K
+2.30%
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
284.97K
+2.30%
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
284.97K
+2.30%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
186.39K
+8.79%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
186.39K
+8.79%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
186.39K
+8.79%
FAQs
Who are the top five shareholders of CAMP4 Therapeutics Corp?
The top five shareholders of CAMP4 Therapeutics Corp are: Mr. Josh Mandel-Brehm
How many institutions hold shares of CAMP4 Therapeutics Corp (CAMP)?
As of 2026Q1, 89 institutions hold shares of CAMP4 Therapeutics Corp, with a combined market value of approximately 42.58M, accounting for 82.01% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 14691076.00.